Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

HeartSciences (HSCS) Research & Development (2021 - 2026)

HeartSciences (HSCS) has disclosed Research & Development for 5 consecutive years, with $727026.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development fell 39.36% year-over-year to $727026.0, compared with a TTM value of $3.7 million through Oct 2025, down 7.36%, and an annual FY2025 reading of $4.4 million, up 52.37% over the prior year.
  • Research & Development was $727026.0 for Q4 2025 at HeartSciences, down from $997206.0 in the prior quarter.
  • Across five years, Research & Development topped out at $1.4 million in Q2 2022 and bottomed at $401114.0 in Q3 2021.
  • Average Research & Development over 5 years is $802849.5, with a median of $742164.5 recorded in 2023.
  • The sharpest move saw Research & Development plummeted 60.58% in 2023, then soared 116.56% in 2024.
  • Year by year, Research & Development stood at $545773.0 in 2021, then surged by 55.55% to $848976.0 in 2022, then dropped by 10.8% to $757303.0 in 2023, then surged by 58.32% to $1.2 million in 2024, then plummeted by 39.36% to $727026.0 in 2025.
  • Business Quant data shows Research & Development for HSCS at $727026.0 in Q4 2025, $997206.0 in Q3 2025, and $929091.0 in Q2 2025.